Skip to main navigation Skip to search Skip to main content

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells

Warren Fiskus, Michael Pranpat, Maria Balasis, Purva Bali, Veronica Estrella, Sandhya Kumaraswamy, Rekha Rao, Kathy Rocha, Bryan Herger, Francis Lee, Victoria Richon, Kapil Bhalla

Research output: Contribution to journal › Article › peer-review

99   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science